PLAN B (levonorgestrel) by Teva is demonstrated. First approved in 1999.
Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
Plan B (levonorgestrel) is an oral emergency contraceptive tablet approved in 1999 that prevents pregnancy through multiple mechanisms including cervical mucus thickening, sperm immobilization, and endometrial alteration. It is taken as a single dose following unprotected intercourse to prevent fertilization. The drug works as a progestin-based contraceptive available over-the-counter in many markets.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely lean and focused on market defense and cost management rather than growth initiatives.
demonstrated. Studies of LNG-releasing IUSs suggest several mechanisms for pregnancy prevention: prevention of fertilization due to the thickening of the cervical mucus, which inhibits sperm passage through the cervix, and inhibition of sperm mobility and function (capacitation), and alteration of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on PLAN B at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Plan B offers exposure to mature product management, OTC marketing strategies, and defense against generic competition in a sensitive therapeutic area. This role is best suited for professionals interested in life-cycle management, market access, and navigating regulatory complexity around women's health products rather than launching growth-stage innovations.